Compare

MOTS-c vs NAD+

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

82 users report co-tracking this pair (47% of MOTS-c trackers also track NAD+).

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
XRedditFacebook

MOTS-c

111 community reports

Positive 17% · Neutral 2% · Negative 81%

Most reported benefits

Appetite
230
Energy
45
Mood
1
Recovery
1

Most reported side effects

Injection site irritation
191

Dose distribution

Median: 2000+ mcg · Most common: 2000+ mcg

0–25
4
25–50
0
50–100
0
100–200
1
200–400
8
400–600
11
600–1000
8
1000–2000
42
2000+
157

How repeat users are trending

Among repeat reporters, 56% said they felt similar to their last entry, 31% more positive, and 13% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 44 days · Based on 45 repeat reporters

NAD+

96 community reports

Positive 2% · Neutral 98% · Negative 0%

Most reported benefits

Energy
197
Appetite
197

Most reported side effects

Headache
66
Nausea
64
Injection site irritation
64

Dose distribution

Median: 2000+ mcg · Most common: 2000+ mcg

0–25
0
25–50
0
50–100
0
100–200
2
200–400
17
400–600
8
600–1000
1
1000–2000
2
2000+
167

How repeat users are trending

Among repeat reporters, 95% said they felt similar to their last entry, 5% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 51 days · Based on 42 repeat reporters